Company Overview
Abpro Corporation operates as a biotechnology firm dedicated to the development of novel antibody constructs specifically for applications in immuno-oncology and ophthalmology. The company utilizes proprietary platforms such as DiversImmune, which functions as a discovery engine to generate a diverse collection of antibodies against both clinically validated and novel targets, alongside its MultiM platform. This entity functions within the Healthcare sector, specifically under the Biotechnology industry classification, a domain characterized by high research and development costs and significant regulatory hurdles before products reach commercialization. The company's market capitalization stands at $1.42M, while its annual revenue is not available for reporting, and it employs a workforce of 6 individuals. These valuation and scale metrics indicate that Abpro Corporation is a micro-cap entity with a very small operational footprint, suggesting it is in an early-stage development phase where revenue generation has not yet materialized to traditional financial reporting standards.
Financial Health
The company reports a Net Income of $-22,040,000 over the trailing twelve months, while its EBITDA stands at $-9,301,000, and Revenue is listed as not available. The substantial negative net income relative to the negative EBITDA reveals a cost structure heavily influenced by non-cash expenses or significant one-time charges that do not appear in the EBITDA calculation, highlighting the intense burn rate typical of early-stage biotechnology firms. Despite the reported net losses, the company reports Free Cash Flow of $6.37M, which provides a critical buffer for financial flexibility by allowing the firm to fund operations and research without immediate external capital injection. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, indicating that the company has not yet achieved commercial profitability or that its revenue base is too small to generate measurable margins under current accounting standards. On the balance sheet, the company holds $328,000 in cash against $147,000 in debt, creating a net cash position, though the Debt to Equity ratio is not available. The Current Ratio is listed at 0.07, a figure that indicates severe short-term liquidity constraints, as current liabilities significantly exceed current assets, suggesting a reliance on long-term financing or equity issuance to meet immediate obligations. Return on Equity is not available, while Return on Assets is recorded at -229.6%, a metric that reveals that for every dollar of assets held, the company generates substantial negative returns, reflecting the capital-intensive nature of its development stage and the lack of revenue to offset asset holdings.
Valuation Assessment
The Trailing Twelve Months P/E Ratio and Forward P/E are both listed as not available, implying that the company is currently unprofitable and therefore cannot be valued using standard earnings multiples. The Price to Book ratio is recorded at -0.09, a negative figure that indicates the market capitalization is less than the company's book value, often seen in distressed or pre-revenue biotech firms where intangible assets are not fully captured on the balance sheet. The Price to Sales ratio is infinite, and the EV/EBITDA is -0.19, suggesting that traditional revenue-based or earnings-based valuation models are not applicable due to the absence of positive earnings and the lack of a defined sales base. The stock's 52-Week High is $18.03, while the 52-Week Low is $0.11, meaning the current trading price sits within a highly volatile range that spans two orders of magnitude. The Beta is recorded as -0.00, a unique and anomalous metric that suggests the stock's price movement has no positive correlation with the broader market, effectively behaving as a neutral or inverse asset in terms of standard beta calculations.
Growth & Income
Revenue Growth year-over-year and Earnings Growth year-over-year are both listed as not available, preventing a direct comparison of earnings growth speed relative to revenue expansion. As a non-dividend payer, the company reports a Dividend Yield of not available and a Payout Ratio of 0.0%, confirming that all retained earnings and cash flows are reinvested into research, development, and operational growth rather than distributed to shareholders. This reinvestment strategy is consistent with the lifecycle of a biotechnology company that prioritizes platform development and clinical trial advancement over immediate income generation for investors. The overall growth and income profile is characterized by a complete absence of current earnings growth or dividend income, relying entirely on the potential future success of its immuno-oncology and ophthalmology antibody platforms to drive future value creation.